GeneDx will pay up to $33 million in cash upon the deal's expected closing this quarter. GeneDx could spend up to $51 million ...

Trump signs EO on drug pricing, supports PhRMA reforms for Medicare negotiations timeline, calls for Canadian drug imports, ...

European regulators on Tuesday authorized the use of Biogen and Eisai’s Alzheimer’s treatment Leqembi for some early-stage ...

In a sign of life for the digital therapeutics industry, Click Therapeutics has received FDA clearance with its treatment for ...

A bipartisan group of 39 state attorneys general is calling on congressional leadership to pass a bill that would prohibit ...

The Johnson & Johnson CEO subtly but assertively criticized the Trump administration’s plans for pharmaceutical tariffs, ...

Boston and Dublin biotech Mural Oncology is laying off nearly all of its employees and ending clinical development of its ...

The centerpiece of Bristol Myers Squibb’s $13 billion MyoKardia acquisition failed a Phase 3 study meant to expand the ...

Attovia Therapeutics is turning fundraising announcements into an annual tradition. In June 2023, the San Carlos, CA-based ...

Roche devastated the Angelman syndrome community in 2023, when it ended clinical development of rugonersen, a treatment ...

A US trade probe into pharmaceuticals is underway. And it’s hitting many of the key aspects of the supply chain.

Boehringer Ingelheim licenses Cue Biopharma's CUE-501 bispecific antibody for $12M upfront, $345M in milestones to target autoimmune diseases via B cell depletion.